Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Cancers (Basel). 2022 Dec 2;14(23):5966. doi: 10.3390/cancers14235966.
Cancers (Basel). 2022.
PMID: 36497447
Free PMC article.
The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab.
Lieb S, Ebel S, Seehofer D, Berg T, van Bömmel F.
Lieb S, et al.
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):148-150. doi: 10.21037/hbsn-22-280. Epub 2023 Jan 16.
Hepatobiliary Surg Nutr. 2023.
PMID: 36860264
Free PMC article.
No abstract available.
Item in Clipboard
Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.
Lieb S, Heni M, Rauschenberg S, Lange K, Feisthammel J, Bläker H, Wiegand J.
Lieb S, et al.
Z Gastroenterol. 2023 Nov;61(11):1500-1503. doi: 10.1055/a-2008-0979. Epub 2023 Feb 3.
Z Gastroenterol. 2023.
PMID: 36736346
English.
Item in Clipboard
Cite
Cite